Morgan Stanley’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-111,434
| Closed | -$246K | – | 7754 |
|
|
2023
Q2 | $246K | Sell |
111,434
-205,414
| -65% | -$426K | ﹤0.01% | 5551 |
|
|
2023
Q1 | $805K | Buy |
316,848
+176,116
| +125% | +$348K | ﹤0.01% | 4982 |
|
|
2022
Q4 | $263K | Sell |
140,732
-55,958
| -28% | -$140K | ﹤0.01% | 5556 |
|
|
2022
Q3 | $505K | Sell |
196,690
-12,554
| -6% | -$31.2K | ﹤0.01% | 5265 |
|
|
2022
Q2 | $405K | Buy |
209,244
+112,618
| +117% | +$246K | ﹤0.01% | 5523 |
|
|
2022
Q1 | $286K | Buy |
96,626
+20,855
| +28% | +$78.5K | ﹤0.01% | 5719 |
|
|
2021
Q4 | $340K | Sell |
75,771
-88,062
| -54% | -$418K | ﹤0.01% | 5776 |
|
|
2021
Q3 | $795K | Buy |
163,833
+14,174
| +9% | +$78.1K | ﹤0.01% | 5203 |
|
|
2021
Q2 | $1.02M | Sell |
149,659
-87,143
| -37% | -$705K | ﹤0.01% | 5066 |
|
|
2021
Q1 | $1.67M | Buy |
236,802
+127,529
| +117% | +$918K | ﹤0.01% | 4395 |
|
|
2020
Q4 | $684K | Sell |
109,273
-437,183
| -80% | -$2.57M | ﹤0.01% | 4884 |
|
|
2020
Q3 | $2.96M | Sell |
546,456
-138,367
| -20% | -$685K | ﹤0.01% | 3277 |
|
|
2020
Q2 | $3.57M | Buy |
684,823
+653,651
| +2,097% | +$2.9M | ﹤0.01% | 3020 |
|
|
2020
Q1 | $99K | Sell |
31,172
-31,368
| -50% | -$116K | ﹤0.01% | 5197 |
|
|
2019
Q4 | $252K | Buy |
62,540
+26,789
| +75% | +$92.9K | ﹤0.01% | 5314 |
|
|
2019
Q3 | $154K | Buy |
35,751
+10,998
| +44% | +$44K | ﹤0.01% | 5266 |
|
|
2019
Q2 | $98K | Sell |
24,753
-17,800
| -42% | -$84.7K | ﹤0.01% | 5334 |
|
|
2019
Q1 | $229K | Sell |
42,553
-50,435
| -54% | -$326K | ﹤0.01% | 4985 |
|
|
2018
Q4 | $478K | Sell |
92,988
-1,847
| -2% | -$14K | ﹤0.01% | 4813 |
|
|
2018
Q3 | $920K | Sell |
94,835
-20,783
| -18% | -$210K | ﹤0.01% | 4600 |
|
|
2018
Q2 | $1.18M | Sell |
115,618
-90,315
| -44% | -$1.02M | ﹤0.01% | 4504 |
|
|
2018
Q1 | $2.68M | Buy |
205,933
+32,255
| +19% | +$480K | ﹤0.01% | 3699 |
|
|
2017
Q4 | $3.11M | Buy |
173,678
+22,968
| +15% | +$479K | ﹤0.01% | 3610 |
|
|
2017
Q3 | $3.78M | Buy |
150,710
+9,787
| +7% | +$228K | ﹤0.01% | 3266 |
|
|
2017
Q2 | $3.4M | Sell |
140,923
-13,770
| -9% | -$304K | ﹤0.01% | 3294 |
|
|
2017
Q1 | $2.98M | Buy |
154,693
+95,243
| +160% | +$1.5M | ﹤0.01% | 3442 |
|
|
2016
Q4 | $916K | Buy |
59,450
+50,361
| +554% | +$654K | ﹤0.01% | 4536 |
|
|
2016
Q3 | $119K | Sell |
9,089
-4,760
| -34% | -$63.1K | ﹤0.01% | 5238 |
|
|
2016
Q2 | $193K | Buy |
13,849
+10,396
| +301% | +$153K | ﹤0.01% | 4956 |
|
|
2016
Q1 | $53K | Buy |
3,453
+482
| +16% | +$7.37K | ﹤0.01% | 5590 |
|
|
2015
Q4 | $56K | Sell |
2,971
-151
| -5% | -$2.88K | ﹤0.01% | 5670 |
|
|
2015
Q3 | $59K | Sell |
3,122
-42
| -1% | -$1.05K | ﹤0.01% | 5667 |
|
|
2015
Q2 | $81K | Sell |
3,164
-10,586
| -77% | -$300K | ﹤0.01% | 5693 |
|
|
2015
Q1 | $430K | Sell |
13,750
-10,574
| -43% | -$304K | ﹤0.01% | 4764 |
|
|
2014
Q4 | $938K | Buy |
24,324
+23,626
| +3,385% | +$564K | ﹤0.01% | 4205 |
|
|
2014
Q3 | $17K | Sell |
698
-508
| -42% | -$13.3K | ﹤0.01% | 6062 |
|
|
2014
Q2 | $29K | Buy |
1,206
+333
| +38% | +$10.9K | ﹤0.01% | 5930 |
|
|
2014
Q1 | $32K | Sell |
873
-260
| -23% | -$10.3K | ﹤0.01% | 5848 |
|
|
2013
Q4 | $45K | Sell |
1,133
-3,775
| -77% | -$160K | ﹤0.01% | 5630 |
|
|
2013
Q3 | $187K | Buy |
4,908
+2,365
| +93% | +$84.7K | ﹤0.01% | 4916 |
|
|
2013
Q2 | $92K | Buy |
+2,543
| New | +$109K | ﹤0.01% | 5095 |
|
Morgan Stanley's PRTK Position: Q3 2023 in Review
Morgan Stanley sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 111,434 shares — an estimated $246K sold.
Morgan Stanley first reported a position in PRTK in Q2 2013 and held it in 41 quarters. The position peaked at $3.78M in Q3 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Morgan Stanley reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 111,434 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $246K.
- Morgan Stanley first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Morgan Stanley's Paratek Pharmaceuticals, Inc. position peaked at $3.78M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.